undamentalytics Newsletter
Sign in

CG Oncology, Inc. revenue

CG Oncology, Inc.'s revenue was $4.0m in fiscal 2025, up 254.7% on the year before. Over the last twelve months it was $6.2m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue2041,1394,0406,228
Growth on the year before—+458.3%+254.7%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Commercial and Development Revenue $3.2M 80.0% —
License and Collaboration Revenue $806,000 20.0% ▼ 29.2%

From CG Oncology, Inc.'s 10-K filed February 27, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
CG Oncology, Inc. $6.2m 1030.3% —
Fate Therapeutics Inc $6.5m -23.4% -62.1%
HCW Biologics Inc. $6.7m 700.2% 20.4%
Taysha Gene Therapies, Inc. $5.5m -32.3% —
Tscan Therapeutics, Inc. $7.1m 2.2% -24.3%
Immuron Ltd $5.2m 10.9% —

Compare with peers

Head to head: CGON vs FATECGON vs HCWBCGON vs TSHA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from CG Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to CG Oncology, Inc.